Traders should monitor for outcomes from the upcoming FDA Type A meeting, which could clarify the regulatory pathway and timeline for U.S. approval. A positive outcome could significantly revalue the stock given the high unmet need and orphan disease status, while further delays or rejections would likely weigh on sentiment.
Price Chart
Executive Summary
Atara Biotherapeutics announced that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the FDA to discuss the path forward for tabelecleucel (tab-cel) following a Complete Response Letter for its Biologics License Application. The briefing book submitted includes additional data from the ALLELE study and post-marketing experience in Europe to support potential resubmission.
Key Facts
- Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA to address issues raised in the Complete Response Letter for tabelecleucel's BLA issued on January 9, 2026.
- The briefing book includes updated longer-term efficacy data from the ALLELE study, additional supportive data, and post-marketing data from Europe.
- Atara and Pierre Fabre are seeking accelerated approval for EBVALLO (tabelecleucel) for EBV+ PTLD, an ultra-rare disease with high unmet need.
- The FDA previously issued a Complete Response Letter, indicating the application is not approvable in its current form.
Financial Impact
No immediate financial impact disclosed; future commercial potential of tabelecleucel in the U.S. remains uncertain pending FDA feedback.
Risk Factors
- FDA may require additional clinical trials or data, delaying or blocking U.S. approval.
- Tabelecleucel remains unapproved in the U.S., creating ongoing regulatory and commercial uncertainty.
- Atara's market cap remains low ($35M), reflecting skepticism about near-term approval prospects.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-086793 |
| Document: d121575dex991.htm | 0001193125-26-086793 |
| Document: 0001193125-26-086793-index-headers.html | 0001193125-26-086793 |
| Document: 0001193125-26-086793-index.html | 0001193125-26-086793 |
| Document: 0001193125-26-086793.txt | 0001193125-26-086793 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 26, 2026 14w ago | 8-K | $11.17 $8.93 | ▼ −20.05% | ▼ −24.44% | $9.48 (−15.13%) |
Jun 15, 2026 15w ago | 3 | $9.62 $9.89 | ▲ +2.81% | ▲ +1.81% | $9.48 (−1.46%) |
May 7, 2026 21w ago | 8-K | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
May 7, 2026 21w ago | Insider Cluster | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
Apr 24, 2026 23w ago | DEFA14A | $4.99 $8.13 | ▲ +62.83% | ▲ +58.05% | $9.48 (+89.98%) |
Mar 17, 2026 28w ago | S-3 | $5.00 $10.46 | ▲ +109.20% | ▲ +97.67% | $9.48 (+89.60%) |
Mar 12, 2026 29w ago | 8-K | $6.90 $9.92 | ▲ +43.77% | ▲ +33.07% | $9.48 (+37.39%) |
Mar 3, 2026 30w ago | 8-K | $5.42 $10.54 | ▲ +94.46% | ▲ +84.15% | $9.48 (+74.91%) |
Mar 2, 2026 30w ago | Insider Cluster | $4.91 $9.61 | ▲ +95.72% | ▲ +86.40% | $9.48 (+93.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access